三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日披露了《关于控股股东、实际控制人之一暨董事长被留置和立案调查的公 告》（公告编号：2025-022），公司控股股东、实际控制人之一暨董事长张阳先 生被实施留置、立案调查。 现公司收到内蒙古自治区监察委员会签发的《变更留置通知书》，内蒙古自 治区监察委员会已解除对张阳先生的留置措施，变更为责令候查措施。目前，张 阳先生已回到工作岗位正常履职。 证券代码：301293 证券简称：三博脑科 公告编号：2025-027 三博脑科医院管理集团股份有限公司 关于控股股东、实际控制人之一暨董事长解除留置并变更为 责令候查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司将持续关注上述事项的后续进展情况，并严格按照相关规定及时履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《证券日报》《中国证券 报》《上海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn），公司 发布的信息均以在上述指定媒体刊登的信息为准。敬请广大投资者理性投资，注 意投资风险。 三博 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-026 | | | | | | | 占剔除公司回 | | --- | --- | --- | --- | --- | --- | --- | | 股东 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司目前 | 购专用账户股 | | 名称 | | | （元） | （股） | 总股本比例 | 份数量后总股 | | | | | | | | 本的比例 | | TBP | 集中竞价 | 2025.4.18-2025.7.11 | 45.21 | 1,124,600 | 0.546% | 0.554% | 1、股东减持股份情况 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份计划期间届满暨实施情况的公告 公司股东 TBP 3Doctors (HK) Limited 保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日披露了《关于持股 5%以上 ...

Core Insights - Vand Investment recently conducted research on Sanbo Brain Science, highlighting the company's success in the world's first interventional brain-computer interface trial for restoring motor function in patients [1] - The company is expanding its network with new hospital branches in Beijing, Kunming, Xi'an, and Hunan, aiming to enhance medical service capabilities [1] - Sanbo Brain Science is focusing on a nationwide chain operation model and plans to establish over ten group-controlled hospitals while strengthening technological innovation and research成果转化 [1] Company Developments - The chairman's personal reasons do not affect the company's operations [1] - The company has a well-established talent training system, with medical personnel in local hospitals being recruited locally and trained in Beijing [1] - The proportion of medical insurance income varies by region, with Beijing's Sanbo Brain Science having about 30% of its income from insurance, while most out-of-town hospitals exceed this figure [1] Financial Performance - New hospital branches have different ramp-up periods, with Fujian Sanbo typically reaching breakeven in about three years, while Henan Sanbo is expected to improve its operational status in the future [1] - The company has repurchased shares for employee stock ownership plans and will implement this at an appropriate time [1] Market Context - The aging population is leading to an increase in degenerative diseases, particularly in the cardiovascular and neurological sectors, which will influence the company's future business growth [1] - The patient demographic spans a wide age range, from newborns to nonagenarians, with patient sources including reputation, technical training, and local expert collaborations [1] - The company actively fulfills social responsibilities through free clinics, discipline construction, and establishing brain health communities [1] Regulatory Environment - Short-term impacts from medical insurance policies are minimal, but long-term contributions to revenue are expected [1] - The DRG (Diagnosis-Related Group) single disease payment system has varying impacts on different hospital branches [1] - The application of brain-computer interfaces is still in the preliminary experimental verification stage, with more mature applications in neuroregulation for treating elderly Parkinson's disease and epilepsy [1]

Summary of the Conference Call for Sanbo Brain Science Company Overview - **Company**: Sanbo Brain Science - **Industry**: Healthcare, specifically focusing on brain-machine interface technology and neurosurgery Key Points and Arguments Financial Performance - **Revenue Stability**: Revenue for the first half of the year remained flat compared to the previous year, with growth observed in Beijing, Henan, and Fujian regions, while Kunming faced challenges due to relocation [2][3] - **Profit Growth**: Expected single-digit profit growth attributed to supply chain optimization and contributions from newly acquired hospitals, with the Chengdu hospital maintaining positive profitability [2][3] Technological Advancements - **Clinical Trials**: Successful completion of an interventional brain-machine interface trial in Fujian, with plans for another trial in Beijing [2][5] - **Research Collaboration**: Joint research projects with universities focusing on early-stage technology research for epilepsy and Parkinson's disease, with minimal fees charged [10][11] New Hospital Developments - **New Facilities**: Progress on new hospital locations, with the Beijing facility expected to relocate in Q1 2025, and the Kunming facility now operational after relocation [2][6] Industry Challenges - **Impact of DRG Payment System**: The implementation of the DRG (Diagnosis-Related Group) payment system has led to a decrease in inpatient costs by approximately 10%, necessitating an increase in patient volume to offset revenue losses [4][16] - **Market Dynamics**: A shift in patient preferences towards pharmacies and clinics due to perceived cost-effectiveness, impacting hospital visit numbers [16] Future Growth Strategies - **M&A Fund**: Establishment of a 300 million yuan merger and acquisition fund aimed at acquiring and incubating hospitals, with contributions from the company, local governments, and large pharmaceutical companies [4][13] - **Expansion Plans**: Plans to expand into the Yangtze River Delta and Pearl River Delta regions through acquisitions, with a focus on enhancing operational efficiency and service quality [16][17] Clinical Application of Brain-Machine Interface Technology - **Current Status**: The technology is in the early clinical validation stage, primarily focused on experimental verification, with applications in neuro-regulation for conditions like Parkinson's disease and epilepsy [7][9] Talent Acquisition and Incentives - **Attracting Talent**: The hospital offers flexible mechanisms and equity incentives to attract core experts, providing significant career advancement opportunities compared to traditional public hospitals [18][19] Collaboration with Universities - **Resource Utilization**: Collaboration with universities to leverage resources for research and teaching, ensuring high-quality support for clinical and academic endeavors [20] Financial Management of Acquisitions - **Risk Management**: Contracts for new acquisitions include provisions for potential risks such as Medicare deductions and legal disputes, ensuring effective management of hidden liabilities [26] Additional Important Information - **AI Integration**: Current clinical and management operations have not fully integrated AI models, with a cautious approach towards evaluating the effectiveness of such technologies [22][23] - **Patient Volume Trends**: Observations indicate a decline in hospital visits, with a notable increase in business for clinics and pharmacies [16][24] This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and industry challenges.

Group 1: Brain-Computer Interface (BCI) Developments - The first successful case of an interventional brain-computer interface in China was completed on June 14, helping a hemiplegic patient regain motor function [2][3] - This technology demonstrates China's independent innovation capabilities in BCI, marking a significant step in precise control, neural reconstruction, and intelligent rehabilitation [3] - Compared to invasive BCIs, interventional BCIs reduce trauma and recovery time, enhancing safety, although they capture lower intracranial EEG signals [3] Group 2: New Hospital Districts Progress - Beijing Sanbo is planning a new district with 480 beds, expected to be operational by Q1 2026, to improve service capacity [4] - The Kunming Sanbo district relocated in May 2025, upgrading facilities and introducing advanced medical equipment, enhancing diagnostic capabilities [4] - The Xi'an Sanbo district is awaiting fire safety approval to commence operations [4] - The Hunan Sanbo district is under construction, with plans for future opening [4] Group 3: Financial and Operational Insights - In Q1 2025, Beijing Sanbo's medical insurance revenue accounted for approximately 30%, with other hospitals showing higher percentages, such as Chongqing Sanbo at 66% [8] - New hospital districts are expected to increase business scale and revenue post ramp-up period, enhancing overall profit levels [5][9] Group 4: Strategic Development and Mergers - The company aims to establish over 10 group-controlled hospitals nationwide, focusing on key regions to expand its service radius and enhance industry influence [6] - Mergers will target neuro-specialty and general hospitals, particularly in the Yangtze River Delta and Pearl River Delta regions [6] Group 5: Talent Development and Training - The talent training system includes local recruitment, training in Beijing, and incentives for high-end talent to join as entrepreneurs [7] - The company provides a comprehensive platform for professional development and complex case management [7] Group 6: ESG and Community Engagement - The company engages in social responsibility by providing financial aid to impoverished patients and conducting free clinics in remote areas [13] - A new brain health community initiative was launched in May 2025, focusing on a full-service system from prevention to rehabilitation [13] Group 7: Impact of Policies and Regulations - The inclusion of certain BCI projects in the medical insurance guidelines is expected to have a long-term positive impact on revenue [14] - DRG payment systems have varying effects on different hospital types, with specialized hospitals facing less impact due to the complexity of cases [14] Group 8: Clinical Applications of BCI - Current clinical applications of BCI are in the experimental phase, focusing on neuro-regulation for conditions like Parkinson's and epilepsy [15] - Ongoing research includes potential applications for awakening patients in a vegetative state and rehabilitation for stroke victims [15]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sanbo Brain Science, indicating a significant increase in shareholder numbers and a high PE ratio compared to industry averages [1][2] - As of July 4, Sanbo Brain Science's closing price was 50.55 yuan, with a PE ratio of 94.75 times, and a total market capitalization of 10.413 billion yuan [1] - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning Sanbo Brain Science at the 39th rank within the industry [1][2] Group 2 - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Sanbo Brain Science includes clinical medical services, with key products being medical services, pharmaceuticals, and supply chain operations [1] - In the first quarter of 2025, the company reported revenue of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, reflecting a year-on-year growth of 14.56%, with a gross margin of 26.44% [1]

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

Core Points - The company announced a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 1.48 per 10 shares (including tax) to shareholders [1][2][3] - The total cash dividend amount is RMB 30,042,490.99, distributed based on a total share capital of 205,986,987 shares, excluding 2,997,183 shares held in the repurchase account [1][2] - The record date for the distribution is set for July 8, 2025, and the ex-dividend date is July 9, 2025 [2][3] Profit Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [3] - The cash dividend per share, calculated based on the total share capital, is RMB 1.458465, which will be adjusted if there are changes in the total share capital before the distribution [1][4] - The company will not issue bonus shares or convert capital reserves into share capital for the fiscal year 2024 [1][2] Taxation and Payment Method - The cash dividends will be paid directly into the shareholders' accounts through their securities companies or other custodians on the ex-dividend date [3] - Different tax rates will apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different types of shares [2][3] Adjustments and Commitments - Following the profit distribution, the minimum selling price for shareholders who have commitments will be adjusted to RMB 11.01 per share [4] - The company commits to maintaining the cash dividend ratio unchanged in case of any changes in total share capital due to share repurchases or other corporate actions [1][4]

证券代码：301293 证券简称：三博脑科 公告编号：2025-025 三博脑科医院管理集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每 10 股现金分红（含税）=现金分红总额/总股本*10 股=30,042,490.99 元 /205,986,987 股*10 股=1.458465 元（保留到小数点后六位，最后一位直接截取， 不四舍五入）。 3、本次权益分派实施后，除权除息参考价格=除权除息前一交易日收盘价- 按公司总股本（含回购股份）折算的每股现金红利=股权登记日收盘价-0.1458465 元/股。 公司 2024 年度权益分派方案已获 2025 年 5 月 16 日召开的公司 2024 年年度 股东会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司于 2025 年 5 月 16 日召开的 2024 年年度股东会审议通过了《关于 2024 年度利润分配预案的议案》。 以公司总股本205,986, ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].